Zentalis Offering Priced at $3.50, Stock Slides 12% Premarket
ZNTL has more than doubled off its 52-week low of $1.212.
Summary
Zentalis priced its 23 million share offering at $3.50, a 6.6% discount to the last close, and the stock fell 12% to $3.64 in premarket trading. The deal is expected to close Aug. 17, with underwriters holding a 30-day option for 3.45 million additional shares. Gross proceeds are $80.5 million, earmarked for clinical trials and other development costs. This follows the company's Q2 report showing a wider-than-expected loss and a cash runway into late 2027. The offering adds dilution but provides funding for the azenosertib program, which recently reported positive Phase 1b data.
At the time of this announcement, ZNTL was trading at $3.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $297.4M. The 52-week trading range was $1.21 to $6.95. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.